The first FDA-approved pharmacologic
therapy indicated for the treatment
of neurotrophic keratitis
1,2
Learn more at Oxervate.com/HCP
References: 1. OXERVATE (cenegermin-bkbj) full
prescribing information. Dompé. May 2019. 2. FDA
approves first drug for neurotrophic keratitis, a rare
eye disease [FDA news release]. August 22, 2018.
© 2019 Dompé U.S. Inc. All rights reserved.
US-OXE-1900008 06/19
Important Safety Information
WARNINGS AND PRECAUTIONS
Patients should remove contact lenses
before applying OXERVATE and wait
15 minutes after instillation of the
dose before reinsertion.
ADVERSE REACTIONS
The most common adverse reaction
in clinical trials that occurred more
frequently with OXERVATE was eye
pain (16% of patients). Other adverse
reactions included corneal deposits,
foreign body sensation in the eye, ocular
hyperemia, swelling of the eye, and
increase in tears (1%-10% of patients).
For additional safety information,
see accompanying Brief Summary
of Safety Information on the
adjacent page and full Prescribing
Information on Oxervate.com/HCP.
